A Phase 4 interventional study of Vaccination with ACAM2000 in Smallpox Vaccine Adverse Reaction, sponsored by Emergent BioSolutions. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.
Sponsored by Emergent BioSolutions · Phase 4, Interventional, and Basic science
Objectives:
This protocol is being conducted to vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV). The objective of this protocol is to ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data.
Participants will be followed for the duration of the study, an expected average of 90 days as described below in the planned study assessments.
Screening [complete within 14 days before Baseline (Day 0)]:
Baseline (Day 0) prior to vaccination:
-Physical exam and vital signs, urine pregnancy test for all female subjects of child-bearing potential, current medications, assessment for pericarditis/myocarditis.
Baseline (Day 0) vaccination and post-vaccination:
-Vaccination with ACAM2000, vaccination site inspection 30 post-vaccination, unanticipated problems, all adverse events including all cardiovascular adverse events (symptoms and signs), concomitant medications.
Post-vaccination Day 3 (±1):
-Assessment for pericarditis/myocarditis, vaccination site inspection, unanticipated problems, unexpected and serious adverse reactions or complications post-vaccination, all adverse events including all cardiovascular adverse events (symptoms and signs).
Post-vaccination Day 7 (±1):
-Assessment of pericarditis/myocarditis symptoms, urine pregnancy test, vaccination site inspection, unanticipated problems, all adverse events including all cardiovascular adverse events (symptoms and signs), concomitant medications.
Post-vaccination Day 12 (±2), 21 (±3), and 28 (±3):
-Assessment of pericarditis/myocarditis symptoms, urine pregnancy test, vaccination site inspection, unanticipated problems, all adverse events including all cardiovascular adverse events (symptoms and signs), concomitant medications.
End of study post-vaccination Day 35 (±3) or Early Withdrawal:
Vital signs, assessment of pericarditis/myocarditis symptoms, urine pregnancy test, vaccination site inspection, unanticipated problems, all adverse events including all cardiovascular adverse events (symptoms and signs), concomitant medications.
Final Safety Assessment Day 90 (±3):
Assessment for pericarditis/myocarditis, unanticipated problems, unexpected and serious adverse reactions or complications post-vaccination, all adverse events including all cardiovascular adverse events (symptoms and signs).
73 studies on the registry are indexed under Smallpox; 5 are open to participants now.
This study's enrollment of 3,032 is above the median of 150 across 61 interventional studies indexed under Smallpox.
Browse Smallpox studies →Emergent BioSolutions is the lead sponsor of 47 studies on the registry; 7 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The subject, or a household contact or other close/intimate contact of the subject has ANY of the following:
Subject has three or more of the following risk factors:
Cardiovascular disease or heart condition diagnosed by a doctor at any time in the past, with or without symptoms, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV). * To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data.
Biological: Vaccination with ACAM2000
Drug page: ACAM2000
In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs)
Number of subjects with AEs including SAEs up to 90 days after vaccination.
Time frame: Adverse event data was collected from vaccinated participants through Day 90.
Number of Vaccinated Participants With Related Adverse Events
Number of subjects with related AEs up to 90 days after vaccination.
Time frame: Adverse event data was collected from vaccinated participants through Day 90.
Number of Vaccinated Participants With Serious Adverse Events (SAEs)
Number of subjects with SAEs up to 90 days after vaccination.
Time frame: Adverse event data was collected from vaccinated participants through Day 90.
| Milestone | Single Arm Vaccinated With ACAM2000 |
|---|---|
| Started | 3032 |
| Completed | 2788 |
| Not completed | 244 |
Number of subjects with AEs including SAEs up to 90 days after vaccination.
| Participants | Single Arm Vaccinated With ACAM2000 |
|---|---|
| Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs) | 1420 |
Number of subjects with related AEs up to 90 days after vaccination.
| Participants | Single Arm Vaccinated With ACAM2000 |
|---|---|
| Number of Vaccinated Participants With Related Adverse Events | 1190 |
Number of subjects with SAEs up to 90 days after vaccination.
| Participants | Single Arm Vaccinated With ACAM2000 |
|---|---|
| Number of Vaccinated Participants With Serious Adverse Events (SAEs) | 25 |
Collected over Adverse event data was collected from vaccinated participants through Day 90.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Arm Vaccinated With ACAM2000 With AEs | 1/3,032 (0%) | 25/3,032 (0.8%) | 1,413/3,032 (46.6%) |
| Single Arm Vaccinated With ACAM2000 With Related AEs | — | — | 1,190/3,032 (39.2%) |
| Event | Single Arm Vaccinated With ACAM2000 With AEs | Single Arm Vaccinated With ACAM2000 With Related AEs |
|---|---|---|
| Chest painGeneral disorders | 2/3032 | — |
| Non-cardiac chest painGeneral disorders | 2/3032 | — |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/3032 | — |
| Acute coronary syndromeCardiac disorders | 1/3032 | — |
| Acute myocardial infarctionCardiac disorders | 1/3032 | — |
| Angina pectorisCardiac disorders | 1/3032 | — |
| HypersensitivityImmune system disorders | 1/3032 | — |
| AppendicitisInfections and infestations | 1/3032 | — |
| Peritonsillar abscessInfections and infestations | 1/3032 | — |
| Post vaccination autoinoculationInfections and infestations | 1/3032 | — |
| Event | Single Arm Vaccinated With ACAM2000 With AEs | Single Arm Vaccinated With ACAM2000 With Related AEs |
|---|---|---|
| Vaccination site scabGeneral disorders | 1098/3032 | 1089/3032 |
| HeadacheNervous system disorders | 182/3032 | 58/3032 |
| PyrexiaGeneral disorders | 56/3032 | 32/3032 |
| FatigueGeneral disorders | 48/3032 | 15/3032 |
| Vaccination site painGeneral disorders | 46/3032 | 43/3032 |
| CoughRespiratory, thoracic and mediastinal disorders | 45/3032 | 7/3032 |
| NauseaGastrointestinal disorders | 34/3032 | 8/3032 |
| DiarrheaGastrointestinal disorders | 24/3032 | 3/3032 |
| PainGeneral disorders | 23/3032 | 11/3032 |
| Vaccination site pruritusGeneral disorders | 22/3032 | 21/3032 |
The safety population consisted of 3032 participants who were vaccinated, including 208 participants who were vaccinated twice (n= 208 includes two participants who were inadvertently vaccinated twice were included twice in demography and all participant counts).
| Age, Categorical(Participants) | Single Arm Vaccinated With ACAM2000 |
|---|---|
| <=18 years | 1 |
| Between 18 and 65 years | 3013 |
| >=65 years | 18 |
| Sex: Female, Male(Participants) | Single Arm Vaccinated With ACAM2000 |
|---|---|
| Female | 765 |
| Male | 2267 |
| Ethnicity (NIH/OMB)(Participants) | Single Arm Vaccinated With ACAM2000 |
|---|---|
| Hispanic or Latino | 626 |
| Not Hispanic or Latino | 2325 |
| Unknown or Not Reported | 81 |
| Race (NIH/OMB)(Participants) | Single Arm Vaccinated With ACAM2000 |
|---|---|
| American Indian or Alaska Native | 64 |
| Asian | 25 |
| Native Hawaiian or Other Pacific Islander | 13 |
| Black or African American | 744 |
| White | 2123 |
| More than one race | 27 |
| Unknown or Not Reported | 36 |
| Region of Enrollment(participants) | Single Arm Vaccinated With ACAM2000 |
|---|---|
| United States | 3032 |
| Height(cm) | Single Arm Vaccinated With ACAM2000 |
|---|---|
| Mean | 174.3 ± 9.5 |
| Weight(kg) | Single Arm Vaccinated With ACAM2000 |
|---|---|
| Mean | 92.5 ± 20.4 |
| BMI(kg/m^2) | Single Arm Vaccinated With ACAM2000 |
|---|---|
| Mean | 30.4 ± 6.4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Sep 2015, a primary completion of Jul 2021 and a completion of Aug 2021. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ACAM2000